Date:12/6/2007

limited to, difficulties or delays in development, testing, regulatory approval, production and marketing of Remoxy and other potential ORADUR-based products, unexpected delays in the filing of a New Drug Application for Remoxy with the FDA, unexpected adverse side effects or inadequate therapeutic efficacy of Remoxy or other potential ORADUR-based products that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the uncertainty of patent protection for Remoxy and other potential ORADUR-based products and unanticipated research and development and other costs. Further information regarding these and other risks is included in DURECT's Form 10-Q dated November 8, 2007 under the heading "Risk Factors."

'/>"/>

SOURCE DURECT Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
3. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
8. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia